HRP20110785T8 - Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands - Google Patents

Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands

Info

Publication number
HRP20110785T8
HRP20110785T8 HR20110785T HRP20110785T HRP20110785T8 HR P20110785 T8 HRP20110785 T8 HR P20110785T8 HR 20110785 T HR20110785 T HR 20110785T HR P20110785 T HRP20110785 T HR P20110785T HR P20110785 T8 HRP20110785 T8 HR P20110785T8
Authority
HR
Croatia
Prior art keywords
phenyl
represents hydrogen
alkyl group
optionally substituted
dopamine
Prior art date
Application number
HR20110785T
Other languages
English (en)
Croatian (hr)
Inventor
Bart�n� Szalai Gizella
�gain� Csongor �va
Dom�ny Gy�rgy
Gyerty�n Istv�n
Kiss Bla
Laszy Judit
S�ghy Katalin
Schmidt Va
Farkas S�ndor
Koml�di Zsolt
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of HRP20110785T1 publication Critical patent/HRP20110785T1/hr
Publication of HRP20110785T8 publication Critical patent/HRP20110785T8/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B53/00Asymmetric syntheses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/09Geometrical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HR20110785T 2007-04-11 2011-10-26 Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands HRP20110785T8 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700269A HUP0700269A2 (en) 2007-04-11 2007-04-11 Pyrimidinyl-piperazines useful as d3/d2 receptor ligands, pharmaceutical compositions containing them and their use
PCT/HU2008/000032 WO2008125891A2 (en) 2007-04-11 2008-04-10 Pyrimidinyl-piperazines useful as dopamine d3 /d2 receptor ligands

Publications (2)

Publication Number Publication Date
HRP20110785T1 HRP20110785T1 (hr) 2011-11-30
HRP20110785T8 true HRP20110785T8 (en) 2012-04-30

Family

ID=38336883

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20110785T HRP20110785T8 (en) 2007-04-11 2011-10-26 Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands

Country Status (36)

Country Link
EP (1) EP2132185B1 (ko)
JP (1) JP4580464B2 (ko)
KR (1) KR101540821B1 (ko)
CN (1) CN101652351B (ko)
AP (1) AP2460A (ko)
AT (1) ATE518843T1 (ko)
AU (1) AU2008237696B2 (ko)
BR (1) BRPI0809641A2 (ko)
CA (1) CA2682817C (ko)
CO (1) CO6241116A2 (ko)
CR (1) CR11071A (ko)
CU (1) CU23853B1 (ko)
CY (1) CY1111962T1 (ko)
DK (1) DK2132185T3 (ko)
EA (1) EA016174B1 (ko)
EC (1) ECSP099702A (ko)
ES (1) ES2370748T3 (ko)
GE (1) GEP20115272B (ko)
HK (1) HK1134491A1 (ko)
HR (1) HRP20110785T8 (ko)
HU (1) HUP0700269A2 (ko)
IL (1) IL200801A0 (ko)
MA (1) MA31359B1 (ko)
MX (1) MX2009010896A (ko)
MY (1) MY148384A (ko)
NI (1) NI200900179A (ko)
NZ (1) NZ579754A (ko)
PL (1) PL2132185T3 (ko)
PT (1) PT2132185E (ko)
RS (1) RS51979B (ko)
SI (1) SI2132185T1 (ko)
TN (1) TN2009000386A1 (ko)
TW (1) TWI445534B (ko)
UA (1) UA103748C2 (ko)
WO (1) WO2008125891A2 (ko)
ZA (1) ZA200906543B (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9091489B2 (en) 2010-05-14 2015-07-28 Paragon Space Development Corporation Radiator systems
RS55645B1 (sr) * 2010-06-18 2017-06-30 Altos Therapeutics Llc Antagonisti d2, postupci za sintezu i postupci upotrebe
US9376396B2 (en) * 2012-10-22 2016-06-28 AbbVie Deutschland GmbH & Co. KG Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine D3 receptor
HU229987B1 (en) * 2012-11-21 2015-04-28 Richter Gedeon Nyrt Process for the preparation of pyrimidinyl-piperazines
JP7015092B2 (ja) 2016-07-28 2022-02-02 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する含窒素縮環化合物
WO2019146739A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンd3受容体拮抗作用を有する縮環化合物
US11447484B2 (en) 2018-01-26 2022-09-20 Shionogi & Co., Ltd. Cyclic compound having dopamine D3 receptor antagonistic effect
WO2024072930A1 (en) * 2022-09-30 2024-04-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2311776A1 (fr) 1975-05-23 1976-12-17 Sogeras Diamino-2,4 bromo-5 chloro-6 pyrimidines et procede pour leur preparation
US5047406A (en) * 1989-12-06 1991-09-10 Warner-Lambert Co. Substituted cyclohexanols as central nervous system agents
US4957921A (en) 1989-12-06 1990-09-18 Warner-Lambert Company Substituted cyclohexanols as central nervous system agents
SE9802208D0 (sv) 1998-06-22 1998-06-22 Astra Pharma Inc Novel compounds
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands

Also Published As

Publication number Publication date
CA2682817C (en) 2015-11-24
NZ579754A (en) 2011-11-25
AU2008237696A1 (en) 2008-10-23
RS51979B (en) 2012-02-29
HRP20110785T1 (hr) 2011-11-30
CO6241116A2 (es) 2011-01-20
ECSP099702A (es) 2009-11-30
KR20100082713A (ko) 2010-07-19
JP2010523642A (ja) 2010-07-15
CY1111962T1 (el) 2015-11-04
PL2132185T3 (pl) 2011-12-30
CU23853B1 (es) 2012-10-15
CA2682817A1 (en) 2008-10-23
MA31359B1 (fr) 2010-05-03
SI2132185T1 (sl) 2011-11-30
TWI445534B (zh) 2014-07-21
IL200801A0 (en) 2010-05-17
EP2132185B1 (en) 2011-08-03
AU2008237696B2 (en) 2013-03-14
AP2009004970A0 (en) 2009-10-31
DK2132185T3 (da) 2011-10-03
GEP20115272B (en) 2011-08-25
ES2370748T3 (es) 2011-12-22
NI200900179A (es) 2010-06-30
CU20090161A7 (es) 2011-09-21
ATE518843T1 (de) 2011-08-15
AP2460A (en) 2012-09-13
HU0700269D0 (en) 2007-05-29
PT2132185E (pt) 2011-11-21
HUP0700269A2 (en) 2009-04-28
JP4580464B2 (ja) 2010-11-10
TN2009000386A1 (en) 2010-12-31
CN101652351B (zh) 2012-07-04
KR101540821B1 (ko) 2015-07-30
BRPI0809641A2 (pt) 2014-11-11
MY148384A (en) 2013-04-15
WO2008125891A2 (en) 2008-10-23
UA103748C2 (uk) 2013-11-25
MX2009010896A (es) 2009-12-14
WO2008125891A3 (en) 2009-01-08
CR11071A (es) 2009-11-20
EA200901391A1 (ru) 2010-02-26
CN101652351A (zh) 2010-02-17
EP2132185A2 (en) 2009-12-16
EA016174B1 (ru) 2012-02-28
ZA200906543B (en) 2010-06-30
TW201002328A (en) 2010-01-16
HK1134491A1 (en) 2010-04-30

Similar Documents

Publication Publication Date Title
HRP20110785T8 (en) Pyrimidinyl-piperazines useful as dopamine d3/d2 receptor ligands
RS53142B (en) UNITS THAT HAVE ANTAGONISTIC ACTIVITY ON CRTH2
RS52349B (en) 5-SUBSTITUTED HINAZOLINONE DERIVATIVES AS ANTITUMOR AGENTS
EA201170096A1 (ru) Замещенные производные пиримидона
RS52872B (en) PIRAL UNITS
RS54183B1 (en) PIRAZOLE DERIVATIVES
RS53348B (en) PROCEDURE FOR THE PREPARATION OF 3-SUBSTITUTED 2-AMINO-5-HALOBENZAMIDES
RS53627B1 (en) N- (3-Amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
RS52900B (en) Benzoylpyrazole Compound, Process for Production and Production of Herbicides Containing Them
MY157891A (en) Mixtures of mesoionic pesticides
RS51919B (en) BENZOTIAZEPINE DERIVATIVES AND THEIR USE AS AMP AND NMDA RECEPTOR MODULATORS
IN2014CN00532A (ko)
EP2597088A4 (en) P2X4 Receptor Antagonists
ES2421896T3 (es) Compuestos de aril-(imidazol)-metil-fenilo sustituidos como moduladores selectivos de los subtipos de receptores adrenérgicos alfa 2B y/o alfa 2C
RS52590B (en) SUBSTITUTIONED QUINOXALINE TYPE COMPONENTS WITH THE USED PIPERIDINE AND THEIR USE
RS53133B (en) PIRAZOL DERIVATIVES USED AS CCR4 RECEPTOR ANTAGONISTS
MX2009011769A (es) Derivados de piridona como inhibidores de mapk p38a.
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
AR060813A1 (es) Moduladores de mglur5 iii
RS53169B (en) PIRAZOLE COMPOUNDS, THE PROCESS FOR THEIR PRODUCTION AND THE HERBICIDES CONTAINING THEM
WO2008136444A1 (ja) 縮合複素環誘導体
TW200609218A (en) Bicyclic compounds
CR10671A (es) Compuestos azabiciclicos como inhibidores de la recaptacion de monoaminas
MY165634A (en) Pyrazole compounds having therapeutic effect on multiple myeloma
HRP20030610B1 (en) Process for the preparation of mesylates of piperazine derivatives